CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05210283

Acronym

MRD

Enrollment

1017

Registered

2022-01-27

Start date

2021-12-15

Completion date

2027-05-15

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Colorectal, ctDNA

Brief summary

The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up to two years of clinical (passive) follow up.

Interventions

DEVICEMRD

ctDNA MRD test

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Diagnosis of carcinoma of the colon or rectum (patients with lymphomatous, sarcomatous, or neuroendocrine features are not eligible). 2. Post complete surgical resection of CRC, with last surgery occurring within 180 days prior to enrollment are eligible if all of the following conditions are met: 1. in the opinion of the surgeon, all grossly visible tumor was completely resected (curative resection) and 2. histologic evaluation by the pathologist confirms the margins of the resected specimens are not involved by malignant cells. i. Patients with T4 tumors that have involved an adjacent structure (e.g., bladder, small intestine, ovary, etc.) by direct extension from the primary tumor must have had all or a portion of the adjacent structure removed en bloc with the primary tumor and local radiation therapy will not be utilized. 3. Pathologic stage II or III 4. ECOG performance status ≤ 2 (0, 1 or 2). 5. Able to understand and provide informed consent. 6. Willing and able to comply with the study requirements, which includes the collection of approximately 43mL of blood for each research blood draw.

Exclusion criteria

1. Initiated adjuvant therapy for current CRC diagnosis (note: prior neoadjuvant therapy acceptable). 2. Pregnant or breastfeeding at time of enrollment. 3. Prior history of any invasive cancer (including CRC) within the past 3 years prior to informed consent, with the exception of non-melanoma skin cancer. Patients with a prior history of noninvasive (in situ) carcinomas may participate after definitive treatment. 4. Prior transplant history: 1. Prior allogeneic hematopoietic stem cell transplant at any time. 2. Prior solid organ transplant within the last 2 years prior to enrollment. 5. Multiple cancer diagnoses: Synchronous or asynchronous diagnoses (or suspicion) of multiple primary cancers at the time of eligibility screening.

Design outcomes

Primary

Measure	Time frame
To validate the association of circulating tumor DNA (ctDNA) with recurrence-free interval (RFI).	7 years

Secondary

Measure	Time frame
To assess the sensitivity and specificity of ctDNA positivity for subsequent clinical recurrence.	7 years
To assess the contribution of ctDNA on RFI, independent of clinicopathological risk features and other biomarkers	7 years
To assess time from positive ctDNA to clinical recurrence	7 years

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026